Kremer, Daniel M. http://orcid.org/0000-0001-6224-0550
Nelson, Barbara S.
Lin, Lin
Yarosz, Emily L. http://orcid.org/0000-0003-3201-9534
Halbrook, Christopher J. http://orcid.org/0000-0002-3376-3114
Kerk, Samuel A. http://orcid.org/0000-0001-9786-2245
Sajjakulnukit, Peter http://orcid.org/0000-0002-8556-7481
Myers, Amy
Thurston, Galloway
Hou, Sean W.
Carpenter, Eileen S.
Andren, Anthony C.
Nwosu, Zeribe C. http://orcid.org/0000-0003-1641-2045
Cusmano, Nicholas
Wisner, Stephanie
Mbah, Nneka E.
Shan, Mengrou
Das, Nupur K.
Magnuson, Brian
Little, Andrew C. http://orcid.org/0000-0003-0135-1032
Savani, Milan R. http://orcid.org/0000-0003-1776-451X
Ramos, Johanna
Gao, Tina
Sastra, Stephen A.
Palermo, Carmine F.
Badgley, Michael A.
Zhang, Li
Asara, John M.
McBrayer, Samuel K. http://orcid.org/0000-0001-9361-675X
di Magliano, Marina Pasca
Crawford, Howard C.
Shah, Yatrik M. http://orcid.org/0000-0002-2487-4816
Olive, Kenneth P.
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Article History
Received: 16 April 2021
Accepted: 8 July 2021
First Online: 11 August 2021
Competing interests
: C.A.L. has received consulting fees from Astellas Pharmaceuticals and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach: (1) US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015 “Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer”, and (2) US Patent No: 2015126580-A1, 05/07/2015 “Methods for diagnosing and treating oncogenic Kras-associated cancer”. The other authors declare no competing interests.